Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
about
sameAs
A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterizationIL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndromeEmerging drugs for Guillain-Barré syndromeGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIVIG treatment and prognosis in Guillain-Barré syndromeNeurologic symptoms associated with cattle farming in the Agricultural Health StudyLe virus ZikaNeurological diseases and painSialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regenerationThe pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathiesAssessing the global threat from Zika virusFoodborne Campylobacter: infections, metabolism, pathogenesis and reservoirsPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisCampylobacter jejuni fatty acid synthase II: Structural and functional analysis of β-hydroxyacyl-ACP dehydratase (FabZ)Crystal structure of theCampylobacter jejuniCmeC outer membrane channelMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemNeuromuscular disorders and sleep in critically ill patientsHealth-related quality of life in Guillain-Barré syndrome patients: a systematic reviewGlobal Epidemiology of Campylobacter InfectionBibliometric analysis of publications on Campylobacter: (2000-2015)Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in EuropeRisk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe[Guillain-Barré syndrome after exposure to influenza].A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndromeGuillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 casesThe role of chemokines in Guillain-Barré syndrome.Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe diseaseMetabolic and fitness determinants for in vitro growth and intestinal colonization of the bacterial pathogen Campylobacter jejuniAssessment of the duration of protection in Campylobacter jejuni experimental infection in humansClinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.Intact thumb reflex in areflexic Guillain Barré syndrome: A novel phenomenon.Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India.Critical illness polyneuropathy and myopathy: a systematic review.Predictors for good functional outcome after neurocritical care.An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages.Pathogenesis and treatment of immune-mediated neuropathies.Peripheral nervous system manifestations of infectious diseasesIntravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome.
P2860
Q21245233-A5C21DA0-6AC2-452C-A23B-1719D1873BF7Q21296685-97E4B4C3-3395-4F3D-B19B-13C50654C480Q22241376-E38E724A-108F-460D-B28A-DBA4104B4B8EQ22251013-F537B1F4-6CC9-4FBB-984A-A397794D1559Q22252627-EE1F988B-AA98-441C-9CE0-FB334C8A5471Q23916864-5ED4F696-D74C-478D-810D-9BF0938E5EB2Q24261297-D4AD774C-0E66-47B1-B655-F78B15DF7BAAQ26822891-BB908AA7-A02F-4E31-B3DC-071CCAA88068Q26995291-1E63A6F8-D847-44A6-9E25-DDD840925455Q27004097-9EBF6425-9641-4869-928C-D084BAE44B67Q27010603-3A05DB87-EBF4-48D3-800B-F93EE74F5126Q27026021-BF6E057B-66E0-4722-8B7D-605C36043804Q27320796-0F6BE194-DC0A-4660-9709-E7B8D9EA66D5Q27654080-E3034A9F-ACC5-4B4F-94A5-B2B864663842Q27683497-DAC678F2-6FFA-449A-8A9A-1E6FF85A0595Q28075974-265F5AE2-96DB-469F-8D73-7C6F91825A48Q28083435-0E2D1A7B-38D4-4058-A73C-1492541A1B17Q28306474-D0B9D6DD-5974-4893-A497-15201B961CDAQ28396111-3C849691-BC17-4595-BE51-3557689699A1Q28554580-A6015DCB-E191-40D1-A731-F9BB0ACE72EFQ30357675-9BD23C7A-6804-41DC-AB36-AEA1976A01FDQ30374961-3B74BF39-2A72-48A1-A7C6-6F1E3BD63240Q30404728-A9CAE0F3-F55F-4F5B-8BF4-42D167E6B2C3Q30415924-06331227-0710-4020-AFC3-79D058FA60C8Q30565519-A6207728-DF9E-4AEF-8F67-365B67E8CC47Q31123673-843E8B92-0647-41B3-859D-805BB2DEF949Q33624382-F63BDB75-B1C2-4C14-9DCA-3822A63DD456Q33666033-0D760A71-1836-49A2-AE27-58079A0FC4E4Q33707828-950237B1-8D4A-44D4-BFED-69D8C2DC0D03Q33769012-17EBB75E-FA1D-4E44-B85E-656445E6A8C7Q33770375-F25C65C7-7E91-4487-86DA-A3850876CE92Q33877847-BE77469F-04AE-428A-A34E-564CB37D8EFDQ33882766-2D22E36B-1707-4E77-B2CE-977B61505588Q34096385-86191157-0D61-4C8E-BAAC-1E2259A87843Q34153257-E8299D11-D92A-408A-876E-D543A7408DA4Q34167468-BA8FF46E-E797-4F75-BAB7-49D3A4F12350Q34292861-AF5227F0-0AFA-4BA8-A362-2C53D7B01D00Q34409385-EC01BCD9-49CF-4516-B3ED-6D6C4C31679AQ34418510-DF6C6B9E-DC77-45A9-93AB-98352AD93512Q34431762-22E1ABAC-8A32-4612-8407-E4389B6BB09E
P2860
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@ast
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@en
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@nl
type
label
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@ast
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@en
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@nl
prefLabel
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@ast
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@en
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@nl
P3181
P1433
P1476
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
@en
P2093
Liselotte Ruts
P3181
P356
10.1016/S1474-4422(08)70215-1
P407
P577
2008-10-01T00:00:00Z